Performance of prothrombin-proconvertin time as a monitoring test of oral anticoagulation therapy

American Journal of Clinical Pathology

Volumn 107, Issue 6, 1997, Pages 672-680

  Haraldsson, H Magnús ^a   Önundarson, Páll T ^a   Einarsdóttir, Kristín Á ^a   Guõmundsdóttir, Brynja R ^a   Pétursson, Magnús K ^a   Pálsson, Kjartan ^a   Kristinsson, Árni ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Coagulation factor IIc; International normalized ratio; Native prothrombin antigen; Oral anticoagulation; Prothrombin time; Prothrombin proconvertin time

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; THROMBOPLASTIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARBOXYLATION; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTHROMBIN TIME; STANDARDIZATION; TASK PERFORMANCE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0030990538     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.6.672     Document Type: Article

References (28)

1. Quick AJ. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem. 1935;109:73-74.
2. Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost. 1985;53:155-156.
3. Hirsh J, Fuster V. AHA medical/scientific statement special report: guide to anticoagulant therapy; part 2: oral anticoagulants. Circulation. 1994;89:1469-1480.
4. Narayanan S. Preanalytical aspects of coagulation testing. Haematologica. 1995;80(suppl 2):1-6.
5. Owren PA, Aas K. The control of dicoumarol therapy and quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3:201-208.
6. Dzung TL, Weibert RT, Sevilla BK, Donnelly KJ, Rapaport SI. The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods. Ann Intern Med. 1994;120:552-558.
7. Griffin JH, Seligson U, Rapaport SI. Coagulation abnormalities in thrombosisa. Hematology-1995. The Education Program of the American Society of Hematology. Seattle, Wash: American Society of Hematology; 1995:57.
8. Schulman S, Lockner D. Relationship between thromboembolic complications and intensity of treatment during longterm prophylaxis with oral anticoagulants following DVT. Thromb Haemost. 1985;54:137-140.
9. Schulman S, Stigendal L, Jansson JH, Brohult J. Haemorrhagic and thromboembolic complications versus intensity of venous thromboembolism with oral anticoagulants. Acta Med Scand. 1988;224:429-230.
10. Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients. Thromb Haemost. 1989;62:788-791.
11. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest. 1993;92:2131-2140.
12. Blanchard RA, Furie BC, Kruger SF, et al. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med. 1983;101:242-255.
13. Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood. 1990;75:344-349.
14. Kornberg A, Francis CW, Pellegrini VD, Gabriel KR, Marder VJ. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation. 1993;88:454-460.
15. Marder VJ, Shulman NR. Clinical aspects of congenital factor VII deficiency. Am J Med. 1964;37:182-194.
16. Brophy MT, Fiore LD, Lau J, et al. Comparison of a standard and a sensitive thromboplastin in monitoring low intensity oral anticoagulant therapy. Am J Clin Pathol. 1994;102:134-137.
17. Moriarty HT, Lam-Po-Tang PR, Anastas N. Comparisons of thromboplastins using the ISI and INR system. Pathology. 1990;22:71-76.
18. Koepke JA. Coagulation testing systems. In: Koepke JA, ed. Practical Laboratory Hematology. New York, NY: Churchill Livingstone; 1991:329-345.
19. Fihn SD. Aiming for safe anticoagulation. N Engl J Med. 1995;333:54-55.
20. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest. 1995;108(suppl):231s-246s.
21. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
22. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
23. Singer DE, Hylek EM. Optimal oral anticoagulation for patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:1505.
24. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70:725-733.
25. Landefield CS, Beyth RJ. Anticoagulant related bleeding: clinical epidemiology, prediction and prevention. Am J Med. 1993;95:315-328.
26. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;I:175-179.
27. Conolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-355.
28. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.